

Summary of NICE Guidelines

Title	Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion
NICE Reference	TA 229
Date of Review:	13 September 2011
Date of Publication	27 July 2011
Summary of Guidance (Max 250 words)	<ul style="list-style-type: none"> • Dexamethasone intravitreal implant is recommended as an option for the treatment of macular oedema following central retinal vein occlusion (CRVO) • Dexamethasone intravitreal implant is recommended as an option for the treatment of macular oedema following branch retinal vein occlusion (BRVO) when: <ul style="list-style-type: none"> ○ treatment with laser photocoagulation has not been beneficial or ○ treatment with laser photocoagulation is not considered suitable because of the extent of macular haemorrhage • People currently receiving dexamethasone intravitreal implant for the treatment of macular oedema secondary to BRVO who do not meet the criteria specified above should have the option to continue treatment until they and their clinicians consider it appropriate to stop.
Impact on Lab (See below)	■ None
Lab professionals to be made aware	Not applicable
Please detail the impact of this guideline (Max 150 words)	Not applicable

Impact on Lab

- **None:** This NICE guideline has no impact on the provision of laboratory services

- **Moderate:** This NICE guideline has information that is of relevance to our pathology service and may require review of our current service provision.

- **Important:** This NICE guideline is of direct relevance to our pathology service and will have a direct impact on one or more of the services that we currently offer.

Written by: Miss Rachel Jones
Reviewed by: Dr Fiona Ivison